J Cancer 2018; 9(18):3417-3426. doi:10.7150/jca.24591
The Significance of Liquid Biopsy in Pancreatic Cancer
1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
3. Shanghai Pancreatic Cancer Institute, Shanghai 200032, P.R. China
4. Pancreatic Cancer Institute, Fudan University, Shanghai 200032, P.R. China
*Zi-Hao Qi and Hua-Xiang Xu contributed equally to this work.
Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, Jin W, Wang WQ, Wu CT, Ni QX, Yu XJ, Liu L. The Significance of Liquid Biopsy in Pancreatic Cancer. J Cancer 2018; 9(18):3417-3426. doi:10.7150/jca.24591. Available from https://www.jcancer.org/v09p3417.htm
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer. The 5-year survival rate for PDAC remains low because it is always diagnosed at an advanced stage and it is resistant to therapy. A biomarker, which could detect asymptomatic premalignant or early malignant tumors and predict the response to treatment, will benefit patients with PDAC. However, traditional biopsy has its limitations. There is an urgent need for a tumor biomarker that could easily and repeatedly sample and monitor, in real time, the progress of tumor development. Liquid biopsy could be a tool to assess potential biomarkers. In this review, we focused on the latest discoveries and advancements of liquid biopsy technology in pancreatic cancer research and demonstrated how this technology is being used in clinical applications.
Keywords: Circulating tumor cells, Cell-free nucleic acid, Exosomes, Liquid biopsy, Pancreatic cancer